SynAct Pharma takes advantage of new toxicology results and new tablet formulation to re-design and optimize the study programme with AP1189 in Nephrotic Syndrome
SynAct Pharma today announces that the company intends to redesign the phase 2 development program with the lead asset AP1189 in Nephrotic Syndrome (NS). The aim of this is to take advantage of longer treatment periods now possible following new preclinical documentation published on November 5th this year. In addition, the redesigned study will take advantage of the company´s newly developed tablet, published on October 15 this year.The major aim of the redesign will be to increase dosing from four weeks to three months and change from dosing with the AP1189 suspension and instead dose